[1]黄婧,李金慈,苏华,等.大数据技术在药学领域应用的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2023,25(1):80-84.[doi:10.3969/j.issn.1672-271X.2023.01.016]
　HUANG Jing,LI Jinci,SU Hua,et al.Research progress on application of big data technology in pharmacy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2023,25(1):80-84.[doi:10.3969/j.issn.1672-271X.2023.01.016]

点击复制

大数据技术在药学领域应用的研究进展()

分享到62.8K

参考文献/References:

[1]黎建辉，沈志宏，孟小峰. 科学大数据管理：概念、技术与系统[J]. 计算机研究与发展，2017，54（2）：235-247.
[2]Nature [EB/OL].
[2014-08-23]. http://www.nature.com/news/specials/bigdata /index.html.
[3]Uthayasankar S, Muhammad MK, Zahir I, et al. Critical analysis of Big Data challenges and analytical methods[J]. J Business Res, 2017,70: 263-286.
[4]Wang Y, Kung L, Wang WYC, et,al. An integrated Big Data analytics-enabled transformation model: application to health care[J]. Inf Manag,2018,55(1):64-79.
[5]Wang Y, Kung L, Byrd TA. Big data analytics: understanding its capabilities and potential benefits for healthcare organizations[J]. Technol Forecast Soc Change, 2018，126:3-13.
[6]Oppitz M, Tomsu P. Inventing the cloud century[M]. Cham: Springer, 2018.
[7]Yang C, Yu M, Hu F, et al. Utilizing cloud computing to address big geospatial data challenges[J]. Comput Environ Urban Syst, 2017,61:120-128.
[8]敖翼，濮润，卢姗，等. 我国新药创制的模式选择与发展思考[J]. 中国新药杂志，2020，29（2）：136-142.
[9]Rahmani AM, Azhir E, Ali S, et al. Artificial intelligence approaches andmechanisms for big data analytics: asystematic study[J]. PeerJ Comput Sci,2021,7(2):e488.
[10]Tripathi MK, Nath A, Singh TP, et al. Evolving scenario of big data and Artifcial Intelligence (AI) in drug discovery[J]. Mol Divers,2021,25(3):1439-1460.
[11]Fang JS, Yang RY, Gao L, et al．Predictions of BuChE inhibitors using support vector machine (SVM) and naive Bayesian classification techniques in drug discovery[J]. J Chem Inf Model,2013,53( 11):3009-3020.
[12]Kumar H, Raj U, Gupta S, et al. In- silico identification of inhibitors against mutated BCR- ABL protein of Chronic Myeloid Leukemia: A Virtual Screening and Molecular Dynamics Simulation study [J]. J Biomol Struct Dyn, 2016,34（10）:2171- 2183.
[13]王哲. 基于分子对接的虚拟筛选方法的评测、优化和应用[D]. 杭州：浙江大学，2019.
[14]Ivan Nestorov. Whole Body Pharmacokinetic Models[J]. Clin Pharmacokinet, 2003, 42:883-908.
[15]Rioux N, Waters NJ. Physiologically-Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development[J]. Drug Metab Dispos, 2016, 44(7): 934-943.
[16]Dinh JC, Pearce RE, Van Haandel L, et al. Characterization of Atomoxetine Biotransformation and Implications for Development of PBPK Models for Dose Individualization in Children[J]. Drug Metab Dispos, 2016, 44(7): 1070-1079.
[17]李正. 探索新药阿替美唑跨种属障碍人体药动学仿真[D]. 北京：军事科学院，2019.
[18]Kohlmann P, Stillhart C, Kuentz M, et al. Investigating Oral Absorption of Carbamazepine in Pediatric Populations[J]. AAPS J, 2017, 19(6): 1864-1877．
[19]Zhang L, Ai HX, Chen W, et al. CarcinoPred-EL: Novel models for predicting the carcinogenicity of chemicals using molecular fingerprints and ensemble learning methods[J]. Sci Rep, 2017,7(1):2118.
[20]马青云，刘辰，杜海涛，等. 基于高通量分子对接虚拟筛选 SARS-CoV-2 3CL 水解酶中药小分子抑制剂及抗新型冠状病毒肺炎（COVID-19）的中药及其复方预测[J]. 中草药，2020，51（6）：1397-1405.
[21]秦健峰，郝二伟，梁跃辉，等. 基于文献挖掘与分子对接技术的瑶药“十八钻”抗新型冠状病毒活性成分筛选[J]. 中草药，2020，51（8）：2024-2034.
[22]李婧，马小兵，沈杰，等. 基于文献挖掘与分子对接技术的抗新型冠状病毒中药活性成分筛选[J]. 中草药，2020，51（4）：845-850.
[23]徐冰，史新元，罗赣，等. 中药工业大数据关键技术与应用[J]. 中国中药杂志，2020，45（2）：221-232.
[24]杜慧，徐冰，徐芳芳，等. 大数据驱动的热毒宁注射液金青醇沉关键工艺参数辨识研究[J]. 中国中药杂志，2020，45（2）：233-241.
[25]Ma C, Wong H, Chu C, et al. Big data in pharmacy practice: current use, challenges, and the future[J]. Integr Pharm Res Pract, 2015:4 91-99.
[26]凌静，焦正，钟明康. 目标浓度干预概况及研究进展[J]. 中国药学杂志，2013，48（16）：1337-1342.
[27]Zhao CY, Jiao Z, Mao JJ, et al. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients [J]. Br J Clin Pharmacol, 2016, 81: 891-907.
[28]Mould DR, Dubinsky MC. Dashboard systems: pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies [J]. J Clin Pharmacol, 2015, 55 Suppl 3: S51-S59.
[29]高玉成，焦正，黄虹，等. 万古霉素个体化给药决策支持系统的研制[J]. 药学学报，2018，53（1）：104-110.
[30]洪灵鸿. 大数据技术在儿科临床合理用药中的应用初探[D]. 杭州：浙江大学，2018.
[31]Huh D, Matthews BD, Mammoto A, et al. Reconstituting organ-level lung functions on a chip[J]. Science,2010, 328(5986):1662-1668.
[32]Huh D, Hamilton GA, Ingber DE.From 3D cell culture to organs-on-chips[J]. Trends Cell Biol, 2011, 21(12):745-754.
[33]Segall MD, Barber C. Addressing toxicity risk when designing and selecting compounds in early drug discovery[J]. Drug Discov Today, 2014,19(5):688-693.
[34]Zhu X, Kruhlak N. Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data[J]. Toxicology,2014,321:62-72.
[35]Andreu-Perez J, Poon CC, Merrifield RD, et al. Big data for health[J]. IEEE J Biomed Health Inform, 2015,19(4): 1193-1208.

相似文献/References: